Biotech 10 February 2026 - 5 March 2026

CSL Buyback Near 2017 Lows: Why the ASX Biotech Giant Is Under Pressure
···

CSL Buyback Near 2017 Lows: Why the ASX Biotech Giant Is Under Pressure

CSL Limited bought back 110,004 shares for A$13.69 million on April 30, extending its on-market buyback as shares trade near multi-year lows, according to a May 1 ASX filing. CSL shares closed Friday at A$124.84, barely above a 52-week low and less than half the year’s high. Half-year revenue fell 4% to US$8.3 billion, with net profit after tax down 81% to US$401 million.
May 3, 2026
CSL buyback hits 4 million shares as Australian biotech keeps buying after profit shock
···

CSL buyback hits 4 million shares as Australian biotech keeps buying after profit shock

CSL repurchased 59,751 shares for A$8.57 million on March 4, bringing total buybacks to 4.03 million shares and A$739 million under its ongoing program. The company also issued 39,627 shares after employee performance rights were exercised. The buyback, capped at US$750 million, is scheduled to run through June 30. Shares will trade ex-dividend on March 10.
March 5, 2026
Amgen stock slides as Kyowa Kirin halts rocatinlimab trials on cancer concerns
···

Amgen stock slides as Kyowa Kirin halts rocatinlimab trials on cancer concerns

Amgen shares dropped 2.3% to $377.01 after Kyowa Kirin halted all trials of the experimental drug rocatinlimab due to new safety concerns, including cases of malignancy. Kyowa Kirin had already ended its development partnership with Amgen. The decline outpaced broader healthcare and biotech sector losses. Investors await further safety disclosures and Amgen’s next quarterly results in late April.
March 3, 2026
Pfizer stock jumps as PFE taps a Swiss biotech incubator — here’s what Wall Street is watching next
···

Pfizer stock jumps as PFE taps a Swiss biotech incubator — here’s what Wall Street is watching next

Pfizer shares rose 2.1% to $27.62 Tuesday afternoon after Swiss incubator BaseLaunch announced Pfizer as its newest pharma partner. The move outpaced a flat U.S. healthcare sector. Investors remain focused on Pfizer’s 2026 pipeline and recent obesity-drug data. The FDA granted Priority Review for Pfizer’s hemophilia drug HYMPAVZI, with a decision expected in Q2 2026.
February 10, 2026